Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ganirelix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 12/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.82 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganirelix SCHEMBL13625244 | 1.00 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL13624942 | 1.00 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL17034758 | 0.97 | GNRHR (0.83) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL8261645 | 0.96 | GNRHR (0.83) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL16298564 | 0.96 | GNRHR (0.83) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL4405429 | 0.95 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL19712192 | 0.95 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL719978 | 0.95 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL20521061 | 0.94 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL29402980 | 0.94 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4687925-A1 | THYMIC CELL COMPOSITIONS AND METHODS OF MAKING | Thymmune Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4534145-A2 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION | Ferring B.V. (NL) | 2025-04-09 | — | — | EP | disclosed |
| EP-4516354-A2 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | Ferring BV (NL) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024211601-A9 | THYMIC CELL COMPOSITIONS AND METHODS OF MAKING | THYMMUNE THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| US-11369613-B2 | Salts and solid form of a BTK inhibitor | PRINCIPIA BIOPHARMA INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022122899-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | FERRING B.V. (NL) | 2022-06-16 | — | — | WO | disclosed |
| EP-4011386-A1 | COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONISTS | Veru Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3973982-A1 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION | Ferring B.V. (NL) | 2022-03-30 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3576771-B1 | COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONISTS | VERU INC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040612-A1 | INJECTABLE HYDROGELS AND METHODS OF CAPTURING CELLS USING THE SAME | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | GNRHR 834/4885DRD1 3329/4885OPRM1 1752/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | GNRHR 743/4885DRD1 302/4885OPRM1 1215/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | GNRHR 834/4885DRD1 3329/4885OPRM1 1752/4885 |
| US-11369613-B2 | Salts and solid form of a BTK inhibitor | BTK, SYK, JAK1 | GNRHR 3892/4885DRD1 3889/4885OPRM1 3996/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | GNRHR 510/4885DRD1 3675/4885OPRM1 453/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | GNRHR 3407/4885DRD1 3490/4885OPRM1 1506/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | GNRHR 2653/4885DRD1 2192/4885OPRM1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.